This technical guide examines the multi-target signaling profile of combining a growth hormone secretagogue receptor agonist, a growth hormone-releasing hormone analog, and a pineal-derived tetrapeptide in laboratory models. Explore analytical benchmarks, receptor interactions, and pharmacokinetic data for these high-purity research compounds.
This technical guide examines the multi-target signaling profile of combining a growth hormone secretagogue receptor agonist, a growth hormone-releasing hormone analog, and a pineal-derived tetrapeptide in laboratory models. Explore analytical benchmarks, receptor interactions, and pharmacokinetic data for these high-purity research compounds.
In preclinical laboratory settings, the combination of ipamorelin + epithalon + cjc-1295 no dac represents a multi-pathway experimental framework designed to evaluate neuroendocrine modulation, somatotrophic axis activation, and cellular longevity signaling simultaneously. CJC-1295 No DAC serves as a selective growth hormone-releasing hormone (GHRH) analog, Ipamorelin acts as a highly selective growth hormone secretagogue receptor (GHSR-1a) agonist, and Epithalon functions as a pineal-derived tetrapeptide investigated for telomerase activation and chromatin remodeling.
When evaluated together in vitro or in animal models, these three distinct compounds target non-overlapping receptor networks. While CJC-1295 No DAC and Ipamorelin exert dual, synergistic stimulation on pituitary somatotrophs to elevate pulsatile growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1), Epithalon operates primarily through epigenetic regulation, pineal gland gene expression, and telomere maintenance. Investigating these distinct mechanisms in tandem provides researchers with a robust model for analyzing tissue repair, metabolic homeostasis, and cellular senescence without inducing receptor desensitization.
To ensure precise, reproducible experimental data across in vitro assays and animal studies, investigators must utilize pure research compounds manufactured under strict analytical standards. Impurities, residual trifluoroacetic acid (TFA), or bacterial endotoxins can confound physiological assays and alter cellular signaling responses.
At PX1 Research, every batch of material undergo rigorous analytical protocols inside ISO 17025 accredited testing facilities. Researchers evaluating these compounds can verify structural integrity and batch-to-batch consistency via public documentation:
• Manufacturing Compliance: Synthesized in modern USA-based, GMP-compliant facilities utilizing solid-phase peptide synthesis (SPPS). • HPLC Purity Verification: High-Performance Liquid Chromatography (HPLC) confirms a minimum peptide purity of 99% for all lots. • Mass Spectrometry Data: High-resolution Mass Spectrometry (MS) verifies precise molecular weight and amino acid sequence identification. • Endotoxin Testing: Standardized LAL assays ensure endotoxin levels remain below strictly monitored research thresholds (<0.5 EU/mg). • Distribution Standards: Same-day dispatch on orders placed Monday through Friday, shipped directly from controlled distribution hubs in California and Arizona.
The cjc-1295 no dac research peptide (also known as Modified GRF 1-29) is a 29-amino-acid synthetic peptide corresponding to the amino-terminal fragment of endogenous GHRH. Standard native GHRH exhibits a rapid terminal half-life of less than 10 minutes in plasma due to swift enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). The chemical structure of CJC-1295 No DAC incorporates four strategic amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) that shield the peptide backbone from rapid enzymatic cleavage while enhancing binding affinity to the GHRH receptor.
In preclinical animal models, CJC-1295 No DAC demonstrates an extended plasma half-life of approximately 30 minutes, allowing for natural, physiological pulses of pituitary GH release. Because it lacks the Drug Affinity Complex (DAC), it does not covalently bind to serum albumin. This fundamental structural distinction prevents the continuous, tonic elevation of baseline growth hormone levels, preserving the endogenous pulsatile pattern of GH secretion critical for investigating tissue repair and metabolic pathways.
A primary distinction in neuroendocrine research is the functional difference between GHRH analogs containing the Drug Affinity Complex (DAC) and non-DAC variants. Understanding these kinetic differences is critical when designing experimental protocols meant to mimic specific physiological secretion patterns.
The cjc 1295 with dac half life extends to approximately 5 to 8 days in preclinical models. This dramatic expansion in duration is driven by the maleimido-propionic acid linker added to the Lysine residue at position 30, which rapidly forms a stable covalent bond with circulating plasma albumin upon administration. Consequently, CJC-1295 With DAC causes sustained, continuous activation of GHRH receptors, elevating baseline serum GH and IGF-1 for extended periods.
Conversely, CJC-1295 No DAC exhibits a half-life of 30 minutes, producing discrete, controlled spikes in GH secretion. Researchers seeking to study normal physiological pulsatility without inducing long-term GHRH receptor downregulation or baseline IGF-1 elevation routinely select CJC-1295 No DAC over its DAC-bound counterpart.
Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal peptide epithalamin. Preclinical studies suggest that Epithalon regulates gene expression by interacting directly with the promoter regions of specific genes, influencing chromatin structure, and stimulating the synthesis of telomerase—the ribonucleoprotein enzyme responsible for preserving telomeric repeat sequences at chromosome ends during cellular division.
When procuring material for cellular senescence assays, sourcing an epithalon third party tested lot ensures that researchers are analyzing a peptide free of residual TFA, truncated synthesis sequences, or heavy metals. In rodent models, Epithalon administration has been documented to modulate pineal gland melatonin production, normalize circadian rhythms, reduce lipid peroxidation, and slow baseline cellular aging markers in cultured fibroblast lines.
Detailed characterization of Epithalon via nuclear magnetic resonance (NMR) and mass spectrometry confirms its precise sequence identity, enabling reproducible research across molecular biology, oncology, and gerontology frameworks.
The co-administration of Ipamorelin alongside CJC-1295 No DAC represents one of the most widely studied paradigms in neuroendocrine research. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively targets the ghrelin/growth hormone secretagogue receptor (GHSR-1a). Unlike earlier GHRPs such as GHRP-2 or GHRP-6, Ipamorelin exhibits extreme receptor specificity; preclinical assays confirm it stimulates pituitary GH release without activating glucocorticoid, mineralocorticoid, or prolactin secretion pathways.
When a GHRH agonist like CJC-1295 No DAC is combined with a GHSR-1a agonist like Ipamorelin, the combined effect on pituitary somatotrophs is multiplicative rather than additive. CJC-1295 No DAC increases cAMP production via G-protein coupled GHRH receptors, while Ipamorelin activates the phospholipase C (PLC) pathway to increase intracellular calcium ions. Together, these complementary intracellular cascades produce a robust, physiological pulse of growth hormone that can be quantified in rodent models or in vitro pituitary cell cultures. For detailed study protocols, explore our comprehensive research hub.
When designing multi-compound experimental protocols, researchers frequently compare the somatotrophic and cellular dynamics of CJC-1295 No DAC, Ipamorelin, and Epithalon against other prominent research peptides. For instance, Sermorelin offers a shorter native GHRH chain with a 10-12 minute half-life, making CJC-1295 No DAC preferred for studies requiring longer receptor occupancy. In tissue regeneration research, investigators often combine somatotrophic agents with cytoprotective peptides like BPC-157 or distinct secretagogues such as GHRP-2. Exploring these overlapping signaling pathways allows laboratories to map complex physiological crosstalk across cellular models.
The structural stability of these compounds relies on precise peptide chemistry. CJC-1295 gmp grade production protocols ensure that synthetic sequence fidelity is maintained, preventing truncated peptide fragments from competing for receptor binding sites or causing non-specific cell signaling.
Proper reconstitution and storage procedures are essential to maintain the bioactivity and structural stability of lyophilized research peptides. Lyophilized vials containing CJC-1295 No DAC, Ipamorelin, or Epithalon should be stored in a controlled freezer environment at -20°C prior to reconstitution, protected from direct light exposure.
1. Reconstitution Medium: Use sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose laboratory sampling, or sterile 0.9% Sodium Chloride for immediate in vitro assays. 2. Reconstitution Technique: Allow the lyophilized vial to reach room temperature before adding the diluent. Direct the stream of liquid down the glass wall of the vial rather than directly onto the peptide cake to prevent shear stress. 3. Mixing Protocol: Gently swirl the vial until the cake is fully dissolved. Never shake reconstituted peptide solutions, as physical agitation can cause aggregation or denature tertiary peptide structures. 4. Aliquoting and Storage: Once reconstituted, store peptide solutions at 2°C to 8°C. For long-term liquid storage, divide the reconstituted solution into sterile single-use micro-aliquots and freeze at -80°C to prevent repeated freeze-thaw cycles.
For laboratory equipment, custom synthesis options, or bulk research orders, investigators can set up dedicated institutional purchasing through our wholesale channel or review full product catalogs via our all peptides directory.
What is the primary mechanism of the ipamorelin + epithalon + cjc-1295 no dac combination?
In preclinical research models, this combination targets three distinct pathways: CJC-1295 No DAC activates GHRH receptors, Ipamorelin selectively targets GHSR-1a receptors to stimulate pulsatile growth hormone release, and Epithalon acts as a pineal-derived telomerase activator and epigenetic regulator.
What is the cjc 1295 with dac half life compared to CJC-1295 No DAC?
The cjc 1295 with dac half life is approximately 5 to 8 days due to its covalent binding to serum albumin via the Drug Affinity Complex. In contrast, CJC-1295 No DAC lacks this complex and exhibits a plasma half-life of roughly 30 minutes in animal models.
What standards are required for cjc-1295 gmp synthesis?
cjc-1295 gmp manufacturing requires strict adherence to Good Manufacturing Practices, including solid-phase peptide synthesis in ISO-certified cleanrooms, lot-specific HPLC/MS verification (>99% purity), and stringent LAL endotoxin testing.
Why select a cjc-1295 no dac research peptide over native GHRH?
Native GHRH has an extremely short half-life (<10 minutes) due to swift degradation by DPP-IV enzymes. A cjc-1295 no dac research peptide features specific amino acid substitutions that resist enzymatic cleavage, extending its half-life to ~30 minutes while maintaining physiological GH pulsatility.
How can researchers verify an epithalon third party tested batch?
An epithalon third party tested lot includes an independent Certificate of Analysis (COA) detailing high-performance liquid chromatography (HPLC) for purity percentage, mass spectrometry (MS) for sequence mass identification, and an LAL assay for endotoxin limits.
Can CJC-1295 No DAC and Ipamorelin be reconstituted in the same vial for laboratory research?
In preclinical laboratory settings, scientists frequently co-reconstitute CJC-1295 No DAC and Ipamorelin using sterile Bacteriostatic Water if compatible buffers and pH stability profile parameters are maintained without triggering physical precipitation.
What diluent is recommended for long-term multi-use peptide reconstitution?
Bacteriostatic Water containing 0.9% benzyl alcohol is recommended for multi-entry research vials to inhibit microbial growth when stored at 2°C to 8°C during ongoing experimental assays.
What are the endotoxin limits for PX1 Research compounds?
All PX1 Research compounds undergo quantitative chromogenic LAL testing to confirm endotoxin concentrations remain strictly under <0.5 EU/mg, minimizing inflammatory cellular artifacts in sensitive in vitro and in vivo models.
How does Epithalon influence cellular senescence in vitro?
In vitro research indicates Epithalon induces telomerase activity, promotes telomere elongation in somatic cells, decreases oxidative stress, and regulates chromatin structure to alter expression patterns associated with aging.
Where are PX1 Research peptide products manufactured and shipped from?
PX1 Research peptides are synthesized in USA-based, GMP-compliant facilities. Orders dispatch same-day Monday through Friday directly from distribution hubs in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.